OMISIRGE
Feb 16, 2026
Alternative Therapeutic Strategies Beyond HSCT: Reimagining Curative Options in Hematologic Disease
Summary HSCT is a potentially curative treatment for hematologic malignancies (acute leukemias, lymphomas, multiple myeloma) and bone marrow failure syndromes. In 2025, approximately 26,000 HSCT cases were reported in the 7MM, with Multiple Myeloma/Plasma Cell Dyscrasias having the largest patient pool in th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
